124) k participants in clinical trials testing new treatments for SCLC. |
125) ming more common, resulting in a need for new treatments. |
126) from his earliest paper published in the New England Journal of Medicine in 1949 to |
127) ary of the ASCENT study, published in the New England Journal of Medicine in April 2 |
128) reast01 study originally published in the New England Journal of Medicine. |
129) Studies were conducted in the Americas, New Zealand, Australia, and India. |
130) reported on nine studies from Australia, New Zealand, and the United Kingdom. |
131) s young peoples across Canada, Australia, New Zealand, and the United States. |
132) Many new agents have been developed in recent y |
133) Research is going on to find new agents or strategies to increase HSC m |
134) rent ways to streamline the evaluation of new agents. |
135) ice client; (2) innovative practices test new approaches and innovations that could |
136) martphones and apps that could facilitate new approaches to healthcare delivery and |
137) -PRC2 are promising molecular targets for new approaches to myeloma treatment and pr |
138) ping review describes existing studies of new attention problems and ADHD following |
139) ed the prevalence of and risk factors for new attention problems and ADHD following |
140) Identified gaps in our understanding of new attention problems and ADHD include if |
141) defect model demonstrated 1.6-fold higher new bone formation compared to the PLA-PDA |
142) Bony fusion caused by pathological new bone formation manifests the clinical |
143) y, aberrant chondrocytes promoted ectopic new bone formation through BMP6/pSmad1/5 s |
144) these strategies to predict the number of new cases of COVID-19. |
145) Annually, >600,000 new cases of head and neck cancer (HNC) ar |
146) d including drug-induced autoimmunity and new cases of systemic sclerosis which have |
147) aging of the population, however, raises new challenges in maintaining quality of l |
148) lancing evidence-based standards with the new challenges posed by the pandemic. |
149) zation programs, or conversely, introduce new challenges. |
150) New coronary vessels are added to the hear |
151) previous model in which the formation of new coronary vessels in neonates from vent |
152) ing factors VEGFR3 and DLL4 and generates new coronary vessels in neonates. |
153) rmining the pharmacokinetic properties of new drug candidates as well as for mechani |
154) drug absorption is key to the success of new drug development and efficacious pharm |
155) logical and clinical insights, as well as new drug targets, for cardiovascular disea |
156) cannot be achieved without implementing a new generation of environmental measures t |
add keyword